| Index | — | P/E | — | EPS (ttm) | -0.93 | Insider Own | 1.02% | Shs Outstand | 69.58M | Perf Week | -1.22% |
| Market Cap | 1.30B | Forward P/E | 145.84 | EPS next Y | 0.13 | Insider Trans | -0.24% | Shs Float | 63.76M | Perf Month | 13.15% |
| Enterprise Value | 1.56B | PEG | — | EPS next Q | -0.25 | Short Float | 23.66% | Perf Quarter | -7.57% | ||
| Income | -63.00M | P/S | 1.25 | EPS this Y | — | Short Ratio | 7.33 | Perf Half Y | -6.04% | ||
| Sales | 1.04B | P/B | 9.99 | EPS next Y | — | ROA | -5.49% | Short Interest | 15.09M | Perf YTD | -15.06% |
| Book/sh | 1.87 | P/C | 2.85 | EPS next 5Y | — | ROE | -45.97% | 52W High | 29.65 -39.80% | Perf Year | 27.96% |
| Cash/sh | 6.55 | P/FCF | — | EPS past 3/5Y | — | ROIC | -4.67% | 52W Low | 12.26 45.60% | Perf 3Y | 3.84% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 8.21% 15.26% | Gross Margin | 56.01% | Volatility | 5.05% 5.39% | Perf 5Y | -85.56% |
| Dividend TTM | — | EV/Sales | 1.50 | EPS Y/Y TTM | — | Oper. Margin | -4.13% | ATR (14) | 0.99 | Perf 10Y | -72.13% |
| Dividend Ex-Date | — | Quick Ratio | 2.65 | Sales Y/Y TTM | -7.14% | Profit Margin | -6.08% | RSI (14) | 57.98 | Recom | 2.38 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.18 | EPS Q/Q | 35.42% | SMA20 | 8.28% | Beta | 1.56 | Target Price | 22.94 |
| Payout | 0.00% | Debt/Eq | 5.53 | Sales Q/Q | 5.81% | SMA50 | 4.02% | Rel Volume | 1.28 | Prev Close | 18.67 |
| Employees | 2,500 | LT Debt/Eq | 5.53 | Earnings | Nov 05 | SMA200 | -1.32% | Avg Volume | 2.11M | Price | 17.85 |
| IPO Date | Nov 14, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.35% -0.17% | Net Debt/EBITDA | — | Volume | 2,716,157 | Change | -4.39% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Reiterated | Mizuho Securities | Neutral | $20 → $18 |
| Oct-06-26 | Initiated | Barclays | Equal Weight | $55 → $18 |
| Aug-07-26 | Reiterated | Canaccord Genuity | Buy | $35 → $40 |
| Aug-07-26 | Reiterated | RBC Capital | Outperform | $30 → $26 |
| Jul-28-26 | Resumed | UBS | Neutral | $22 → $18 |
| Jun-23-26 | Downgrade | Deutsche Bank | Buy → Hold | $16 |
| Jun-01-26 | Upgrade | Wells Fargo | Equal Weight → Overweight | $45 → $27 |
| May-27-26 | Reiterated | Goldman Sachs | Neutral | $24 → $21 |
| May-11-26 | Reiterated | Barclays | Overweight | $56 → $55 |
| May-08-26 | Reiterated | Mizuho Securities | Neutral | $22 → $24 |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,041 | 1,015 | 940 | 748 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 458 | 484 | 451 | 380 | — | — | — | — | — | |
| Gross Profit | 583 | 531 | 490 | 368 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 439 | 434 | 390 | 353 | — | — | — | — | — | |
| Research and Development | 187 | 175 | 199 | 248 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -43 | -78 | -99 | -233 | — | — | — | — | — | |
| Interest Expense | 8 | 8 | 7 | 10 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -10 | -114 | 15 | 23 | — | — | — | — | — | |
| Net Income Before Taxes | -61 | -200 | -92 | -220 | — | — | — | — | — | |
| Income Taxes | 3 | 4 | 4 | 2 | — | — | — | — | — | |
| Consolidated Net Income | -63 | -205 | -96 | -223 | — | — | — | — | — | |
| Net Income From Continuing Operations | -63 | -205 | -96 | -223 | — | — | — | — | — | |
| Net Income | -63 | -205 | -96 | -223 | — | — | — | — | — | |
| EPS (Recurring) | -0.93 | -3.04 | -1.47 | -3.43 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.93 | -3.04 | -1.47 | -3.43 | — | — | — | — | — | |
| EPS (Diluted) | -0.93 | -3.04 | -1.47 | -3.43 | — | — | — | — | — | |
| EBITDA | -36 | -175 | -83 | -196 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.17 | 1.45 | 2.49 | 2.57 | — | — | — | — | — | |
| Gross Margin | 56.00 | 52.32 | 52.13 | 49.20 | — | — | — | — | — | |
| Operating Margin | -4.13 | -7.68 | -10.53 | -31.15 | — | — | — | — | — | |
| Net Margin | -6.05 | -20.20 | -10.21 | -29.81 | — | — | — | — | — | |
| Shares Outstanding | 68 | 67 | 65 | 65 | — | — | — | — | — | |
| Market Capitalization | 1,214 | 1,473 | 2,341 | 1,923 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TWOMEY CHRISTOPHER J | Director | Oct 27 '26 | Option Exercise | 19.00 | 1,700 | 32,300 | 26,134 | Oct 29 |
| TWOMEY CHRISTOPHER J | Director | Oct 27 '26 | Sale | 19.15 | 1,700 | 32,555 | 24,434 | Oct 29 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer | Oct 15 '26 | Option Exercise | 0.00 | 3,637 | 0 | 33,927 | Oct 19 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER | Aug 15 '26 | Option Exercise | 0.00 | 4,120 | 0 | 52,982 | Aug 18 |
| Sheridan John F | PRESIDENT & CEO | Aug 15 '26 | Option Exercise | 0.00 | 15,916 | 0 | 165,315 | Aug 18 |
| Morrison Susan | EVP & Chief Admin. Officer | Aug 15 '26 | Option Exercise | 0.00 | 2,827 | 0 | 53,283 | Aug 18 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer | Aug 15 '26 | Option Exercise | 0.00 | 1,010 | 0 | 30,825 | Aug 18 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer | Aug 15 '26 | Option Exercise | 0.00 | 3,014 | 0 | 2,425 | Aug 18 |
| Carpenter Rick | EVP & Chief Technology Officer | Aug 15 '26 | Option Exercise | 0.00 | 2,507 | 0 | 32,968 | Aug 18 |
| Hansen Shannon Marie | EVP & Chief Legal Officer | Aug 15 '26 | Option Exercise | 0.00 | 3,014 | 0 | 32,626 | Aug 18 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer | Jul 15 '26 | Option Exercise | 0.00 | 3,636 | 0 | 31,741 | Jul 17 |
| Malagueira Joao Paulo Falcao | Director | May 21 '26 | Option Exercise | 0.00 | 8,759 | 0 | 22,458 | May 22 |
| Allen Dick | Chair Emeritus | May 21 '26 | Option Exercise | 0.00 | 8,759 | 0 | 28,146 | May 22 |
| Howell Peyton R | Director | May 21 '26 | Option Exercise | 0.00 | 8,759 | 0 | 29,836 | May 22 |
| Sodhi Rajwant | Director | May 21 '26 | Option Exercise | 0.00 | 8,759 | 0 | 24,280 | May 22 |